secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulgent Genetics, Inc. (FLGT)
CIK:        0001674930
Form:       8-K
Filed at:   2022-02-23T23:59:59+00:00
Accession:  0001564590-22-006243
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulgent Genetics Q4 revenue $251.7M, full year 2021 revenue $992.6M, core revenue up 236% YoY
--------------------------------------------------------------------------------

- Q4 revenue $251.7M; full year 2021 revenue $992.6M, up 135% year-over-year.
- Core revenue (ex-COVID) rose 234% YoY to $40.1M in Q4; full year core rev $122.6M (+236%).
- GAAP net income $104.3M ($3.34 EPS) in Q4; full year GAAP net income $507.4M ($16.38 EPS).
- Non-GAAP income $108.7M ($3.48 EPS) in Q4; adjusted EBITDA $159.8M.
- Cash, cash equivalents & marketable securities $935.5M as of Dec 31, 2021; cash from ops $77.1M in Q4.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674930/000156459022006243/0001564590-22-006243-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674930/000156459022006243/flgt-8k_20220223.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-006243

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer